Overview

• US handheld chemical analysis firm's Q1 revenue rose 14%, beating analyst expectations

• Adjusted gross margin rose to 57% from 54% a year earlier

Outlook

• 908 Devices raises 2026 revenue outlook to $67 mln-$70 mln, up 19%-25% from 2025

Result Drivers

• PRODUCT REVENUE GROWTH - Q1 revenue growth was driven by higher product revenue for mass spec, increased placements, and a shift in FTIR product mix

• INSTALLED BASE EXPANSION - Installed base grew 23% year-over-year to 3,903 devices, with 167 devices placed during the first quarter

• GROSS MARGIN IMPROVEMENT - Adjusted gross margin increased due to higher product revenues, a shift in channel mix, and consolidated facilities, partly offset by lower service gross margins

Company press release: ID:nBw3hwDq7a

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Revenue	Beat	$13.40 mln	$13.15 mln (4 Analysts)
Q1 Gross Profit		$6.90 mln
Q1 Operating Expenses		$19.80 mln

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

• Wall Street's median 12-month price target for 908 Devices Inc is $10.00, about 41% above its May 5 closing price of $7.09

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.